Growth Opportunities in Global Pharmaceutical Logistics 2022: Cold Chain Investments and Hybrid Clinical Trials to Ensure Transformational Growth of Pharmaceutical Logistics - ResearchAndMarkets.com
31 Jan 2023
DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Global Pharmaceutical Logistics" report has been added to ResearchAndMarkets.com's offering.
Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure on healthcare supply chains worldwide is driving companies to address vulnerabilities. Pharmaceutical companies will need to rely heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations.
The increasing focus on biologics, adoption of technology, and shift to a patient-centric model are transforming the pharma logistics market; the COVID-19 pandemic has sped up the rate of transformation and acted as a catalyst for the adoption of decentralized trials. This has increased the complexity of coordination of not only clinical trial supply management but also healthcare professionals, and arranging necessary infrastructure for drug storage and infusion.
This research analytics on the global pharmaceutical logistics market identifies some of the leading growth opportunity areas in cold chain capabilities for next-generation vaccines and biologics and hybrid trial logistics ensuring patient enrollment and diversity, highlighting the improved last-mile connectivity to propagate the anytime-anywhere care business model. In addition, the market is witnessing the simultaneous adoption of predictive supply chain solutions that optimize pharma operations and improve profitability.
Key Topics Covered:
1. Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Logistics Industry
Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Analysis
Scope of Analysis
Segmentation
Market Dynamics
Value Chain Analysis
Key Competitors
Vendor Landscape
Growth Drivers for Pharmaceutical Logistics
Growth Restraints for Pharmaceutical Logistics
Regional Analysis - North America (NA)
Regional Analysis - Europe
Regional Analysis - United Kingdom (UK)
Regional Analysis - Asia-Pacific (APAC)
Contract-logistics-provider-related Developments
Supply-chain-solution-provider-related Developments
CDMO-r
CRO-related Developments
Pharma LogisticsPrimed for Business Model Disruption
3. Growth Opportunity Universe
Growth Opportunity Universe - A Summary
Growth Opportunity Universe Summary
Growth Opportunity 1: Repurposing Cold Chain Capabilities
Global Cold-Chain Products Sales
Global Cold-Chain Logistics Spending
Global Cold-Chain Logistics Spending
Growth Opportunity 2: Hybrid Trial Logistics
Case Study - DHL
Case Study - Marken (UPS)
Growth Opportunity 3: Improved Last-mile Connectivity
eCommerce - Disrupting the Traditional Supply Chain Model
Case Study - Capsule
Growth Opportunity 4: Predictive Supply Chain
Case Study - Trek Therapeutics Uses Ambrosus' Blockchain Solution for Quality Control
Case Study - Macro-Eyes' ML Solutions Bring Predictability to the Vaccine Supply Chain
Companies to Action
List of Exhibits
Legal Disclaimer
A selection of companies mentioned in this report includes
Capsule
Marken (UPS)
For more information about this report visit https://www.researchandmarkets.com/r/24rbgs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.